» Articles » PMID: 18832018

Mechanism of Action of ZOT-derived Peptide AT-1002, a Tight Junction Regulator and Absorption Enhancer

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2008 Oct 4
PMID 18832018
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Tight junctions (TJs) are intercellular structures that control paracellular permeability and epithelial polarity. It is now accepted that TJs are highly dynamic structures that are regulated in response to exogenous and endogenous stimuli. Here, we provide details on the mechanism of action of AT-1002, the active domain of Vibrio cholerae's second toxin, zonula occludens toxin (ZOT). AT-1002, a hexamer peptide, caused the redistribution of ZO-1 away from cell junctions as seen by fluorescence microscopy. AT-1002 also activated src and mitogen activated protein (MAP) kinase pathways, increased ZO-1 tyrosine phosphorylation, and rearrangement of actin filaments. Functionally, AT-1002 caused a reversible reduction in transepithelial electrical resistance (TEER) and an increase in lucifer yellow permeability in Caco-2 cell monolayers. In vivo, co-administration of salmon calcitonin with 1 mg of AT-1002 resulted in a 5.2-fold increase in AUC over the control group. Our findings provide a mechanistic explanation for AT-1002-induced tight junction disassembly, and demonstrate that AT-1002 can be used for delivery of other agents in vivo.

Citing Articles

Design of Auto-Adaptive Drug Delivery System for Effective Delivery of Peptide Drugs to Overcoming Mucus and Epithelial Barriers.

Ding R, Li Y, Zheng W, Sun Y, Zhao Z, Zhang H AAPS J. 2024; 26(5):102.

PMID: 39266802 DOI: 10.1208/s12248-024-00971-1.


Preparation, Drug Distribution, and In Vivo Evaluation of the Safety of Protein Corona Liposomes for Liraglutide Delivery.

Ding R, Zhao Z, He J, Tao Y, Zhang H, Yuan R Nanomaterials (Basel). 2023; 13(3).

PMID: 36770503 PMC: 9920406. DOI: 10.3390/nano13030540.


Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.

Kim J, Park E, Na D Pharmaceuticals (Basel). 2022; 15(12).

PMID: 36559036 PMC: 9781085. DOI: 10.3390/ph15121585.


Oral delivery of proteins and peptides: Challenges, status quo and future perspectives.

Zhu Q, Chen Z, Paul P, Lu Y, Wu W, Qi J Acta Pharm Sin B. 2021; 11(8):2416-2448.

PMID: 34522593 PMC: 8424290. DOI: 10.1016/j.apsb.2021.04.001.


Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions.

Slifer Z, Hernandez L, Pridgen T, Carlson A, Messenger K, Madan J PLoS One. 2021; 16(4):e0250165.

PMID: 33886649 PMC: 8061941. DOI: 10.1371/journal.pone.0250165.